*VOLGA study* cis-ineligible/refused @tompowles1 @MichvdHeijden @myESMO #ESMO26 @oncodaily @OncoAlert
🔴 EV+Durva x 3 w ⬆️ pCR, EFS, OS
🟠 ≈20% ❌ cystectomy
🟢 ct-DNA clearance associated w EFS
🔵 ⬆️ toxicity in triplet EV+Durva/T, will reduced dose impact oucomes?
🟣 Less migh be enough, more too much?
54 views · 2 likes · 2 reposts · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: Maite Bourlon · x.com